USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape...
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape...
$2.25 Million Research Collaboration Focused on Understanding and Treating Lung Cancers Harboring HER2 Mutations; call for Requests for Proposals
NEW YORK, June 17, 2025 /PRNewswire/...
Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS)...